Elevated TGF-β1 levels are directly correlated with liver fibrosis severity and have been identified as therapeutic targets in ALD and non-alcoholic steatohepatitis (NASH) [44]. The gene discussed is TGFB1; the disease is metabolic dysfunction-associated steatohepatitis.